

Nerfasin vet. 20 mg/ml, solution for injection for cattle and horses

Authorised

- Xylazine hydrochloride

Product identification

Medicine name:

Nerfasin vet. 20 mg/ml, solution for injection for cattle and horses

Active substance:

Xylazine hydrochloride

Target species:

Cattle

Horse

Route of administration:

Intramuscular use

Intravenous use

Product details

Active substance and strength:

Xylazine hydrochloride

23.31 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:

Intramuscular use:

•

Cattle

- Milk. no withdrawal period 0 days

- Meat and offal. 1 day

•

Horse

- Milk. no withdrawal period 0 days

- Meat and offal. 1 day

Intravenous use:

•

Cattle

- Milk. no withdrawal period 0 days

- Meat and offal. 1 day

•

Horse

- Milk. no withdrawal period 0 hours

- Meat and offal. 1 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN05CM92

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Hungary

Package description:

50 ml product in a 50 ml clear type II glass vials closed with a bromobutyl rubber stopper and aluminium cap in a carton box.

25 ml product in a 30 ml clear type II glass vials closed with a bromobutyl rubber stopper and aluminium cap in a carton box.

10 ml product in a 10 ml clear type II glass vials closed with a bromobutyl rubber stopper and aluminium cap in a carton box.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Le Vet. B.V.

Marketing authorisation date:

24/09/2013

Manufacturing sites for batch release:

Produlab Pharma B.V.

Responsible authority:

Directorate Of Veterinary Medicinal Products

Authorisation number:

3415/X/13 NÉBIH ÁTI

Date of authorisation status change:

24/09/2013

Reference member state:

Netherlands

Procedure number:

NL/V/0157/001

Concerned member states:

Austria Belgium Czechia Denmark Finland France Greece Hungary Iceland
Ireland Italy Luxembourg Norway Poland Portugal Slovakia Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

108956 - par.pdf